Orthocell Limited (ASX:OCC) Insider Paul Anderson Buys 80,426 Shares

Orthocell Limited (ASX:OCC) insider Paul Anderson bought 80,426 shares of the company’s stock in a transaction dated Tuesday, October 15th. The stock was bought at an average cost of A$0.73 ($0.49) per share, with a total value of A$58,710.98 ($39,403.34).

Orthocell Stock Performance

The company has a debt-to-equity ratio of 15.22, a quick ratio of 5.07 and a current ratio of 4.34.

About Orthocell

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia. The company offers CelGro, a naturally derived collagen medical device for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons, and cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries.